Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by Hiddensecretson Jan 20, 2021 2:12pm
205 Views
Post# 32335073

Next week: Jan 26th we QUADRUPLE - $ 50 Billion Biden pie

Next week: Jan 26th we QUADRUPLE - $ 50 Billion Biden pieWe close the bought deal next Tuesday January 26th for $ 5 million. 

Once that is done Cannaccord will aggressively push the stock with a BUY recommendation and a $ 3 per share price target. 

Virus is getting worse around the world and the variants are extremely destructive as they evade the vaccine. 

We are going to have TESTING for years.....

And we are going to be one of the main beneficaires of the $ 50 billion BIDEN plan + the $ 20 billion BIDEN vaccination plan.

If we get 5% of this we have sales of $ 2.5 billion + $ 1 billion, at a 55% profit margin. 

Do the math on earnings per share and you will see that this is a $ 20 stock.

MPO
<< Previous
Bullboard Posts
Next >>